Unisense FertiliTech A/S, Aarhus, Denmark-based medtech company that develops technology to improve human embryo assessment in assisted reproduction, has received a $24m investment.
Oticon Funds investment company William Demant Invest (WDI) now owns 32% after the purchase of new and existing shares in Unisense FertiliTech.
Founded in 2003 and led by CEO Jens Gundersen, Unisense FertiliTech develops and manufactures products to improve treatment in the field of assisted reproduction. Its EmbryoScope® Time-lapse system, the EmbryoViewer® Workstation (Software) and related products are EU approved and FDA cleared for clinical use in IVF laboratories.
The company currently operates in more than 30 countries worldwide. In addition to the current hardware and software product offerings, Unisense is now developing products which hold significant commercial potential within the IVF industry.
The company intends to use the capital to execute its long term development strategy and to accelerate the global expansion of sales of existing and new products.